Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Lapatinib: a sword with two edges Kopper LPathol Oncol Res 2008[Mar]; 14 (1): 1-8Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antineoplastic Agents[MESH]|Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH]|Breast Neoplasms/*drug therapy/metabolism[MESH]|Clinical Trials as Topic[MESH]|Drug Resistance, Neoplasm[MESH]|ErbB Receptors/antagonists & inhibitors/metabolism[MESH]|Female[MESH]|Humans[MESH]|Lapatinib[MESH]|Neoplasms/drug therapy[MESH]|Quinazolines/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Receptor, ErbB-2/antagonists & inhibitors/metabolism[MESH]|Trastuzumab[MESH] |